DK2872896T3 - Status of a tuberculosis infection in an individual - Google Patents
Status of a tuberculosis infection in an individual Download PDFInfo
- Publication number
- DK2872896T3 DK2872896T3 DK13737831.1T DK13737831T DK2872896T3 DK 2872896 T3 DK2872896 T3 DK 2872896T3 DK 13737831 T DK13737831 T DK 13737831T DK 2872896 T3 DK2872896 T3 DK 2872896T3
- Authority
- DK
- Denmark
- Prior art keywords
- level
- tuberculosis infection
- mononuclear cells
- amount
- determining
- Prior art date
Links
- 201000008827 tuberculosis Diseases 0.000 title claims description 129
- 208000015181 infectious disease Diseases 0.000 title claims description 100
- 108010031025 Alanine Dehydrogenase Proteins 0.000 claims description 68
- 210000005087 mononuclear cell Anatomy 0.000 claims description 65
- 108090000695 Cytokines Proteins 0.000 claims description 59
- 102000004127 Cytokines Human genes 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 46
- 108010002350 Interleukin-2 Proteins 0.000 claims description 30
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 26
- 230000000638 stimulation Effects 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 206010065048 Latent tuberculosis Diseases 0.000 claims description 12
- 208000036981 active tuberculosis Diseases 0.000 claims description 11
- 230000007704 transition Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 238000012544 monitoring process Methods 0.000 claims description 9
- 238000011285 therapeutic regimen Methods 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 238000009004 PCR Kit Methods 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 208000033353 latent tuberculosis infection Diseases 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 102100037850 Interferon gamma Human genes 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 101001057048 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ESAT-6-like protein EsxB Proteins 0.000 description 11
- 238000011998 interferon-gamma release assay Methods 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 10
- 238000011510 Elispot assay Methods 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 5
- 238000013517 stratification Methods 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 4
- 239000000021 stimulant Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 229960001005 tuberculin Drugs 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 101900287970 Mycobacterium tuberculosis Alanine dehydrogenase Proteins 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 102100034229 Citramalyl-CoA lyase, mitochondrial Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000020545 Exposure to communicable disease Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- -1 H1 hybrid Proteins 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108020004687 Malate Synthase Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 101100395578 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) hrp1 gene Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010051837 Skin induration Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012774 diagnostic algorithm Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012729 kappa analysis Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
- G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
- G01N2333/90611—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1) in general
- G01N2333/90616—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1) in general with a definite EC number (1.4.1.-)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12176506.9A EP2687848A1 (en) | 2012-07-16 | 2012-07-16 | Status of tuberculosis infection in an individual |
| PCT/EP2013/065002 WO2014012928A1 (en) | 2012-07-16 | 2013-07-16 | Status of tuberculosis infection in an individual |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2872896T3 true DK2872896T3 (en) | 2018-04-09 |
Family
ID=48795573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13737831.1T DK2872896T3 (en) | 2012-07-16 | 2013-07-16 | Status of a tuberculosis infection in an individual |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP2687848A1 (enExample) |
| CN (1) | CN104541169B (enExample) |
| AU (1) | AU2013292040B2 (enExample) |
| CA (1) | CA2878497C (enExample) |
| DK (1) | DK2872896T3 (enExample) |
| EA (1) | EA030721B1 (enExample) |
| ES (1) | ES2666073T3 (enExample) |
| IN (1) | IN2015MN00140A (enExample) |
| NO (1) | NO2872896T3 (enExample) |
| PL (1) | PL2872896T3 (enExample) |
| PT (1) | PT2872896T (enExample) |
| WO (1) | WO2014012928A1 (enExample) |
| ZA (1) | ZA201500254B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3171170A1 (en) * | 2015-11-17 | 2017-05-24 | Lionex GmbH | Device for use in elispot |
| KR20180104038A (ko) * | 2016-01-20 | 2018-09-19 | 시아먼 유니버시티 | 활동성 결핵의 진단을 위한 방법 및 키트 |
| CN106501530A (zh) * | 2017-01-05 | 2017-03-15 | 复旦大学附属华山医院 | 一种诊断结核杆菌感染的生物标志物及其相关试剂盒 |
| RU2726789C1 (ru) * | 2020-01-17 | 2020-07-15 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ФПИ" Минздрава России) | Способ иммунологического определения активности туберкулезной инфекции у детей и подростков с латентной инфекцией |
| CN115598353B (zh) * | 2022-10-24 | 2024-09-13 | 首都医科大学附属北京胸科医院 | 细胞因子作为标记物在制备肺外结核诊断或治疗预后产品中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6641814B1 (en) * | 1997-04-02 | 2003-11-04 | Statens Serum Institut | Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis |
| CA2279255A1 (en) | 1997-01-29 | 1998-08-20 | Flohe, Leopold | Test kit for tuberculosis diagnosis by determining alanine dehydrogenase |
| JP5017269B2 (ja) * | 2005-07-26 | 2012-09-05 | ユニヴァーシティ オブ メディシン アンド デンティストリ オブ ニュージャーシィ | 結核状態に特有の抗体プロフィール |
| DE102007052518A1 (de) * | 2007-10-29 | 2009-04-30 | Autoimmun Diagnostika Gmbh | Verfahren zur in vitro-Diagnose und/oder in vitro- Therapieverfolgung von Infektionen |
| CN102033129A (zh) * | 2009-09-29 | 2011-04-27 | 上海英伯肯医学生物技术有限公司 | 用抗原刺激的细胞免疫反应来检测病原微生物的方法及测试笔 |
-
2012
- 2012-07-16 EP EP12176506.9A patent/EP2687848A1/en not_active Withdrawn
-
2013
- 2013-07-16 EA EA201590220A patent/EA030721B1/ru not_active IP Right Cessation
- 2013-07-16 PT PT137378311T patent/PT2872896T/pt unknown
- 2013-07-16 DK DK13737831.1T patent/DK2872896T3/en active
- 2013-07-16 NO NO13737831A patent/NO2872896T3/no unknown
- 2013-07-16 WO PCT/EP2013/065002 patent/WO2014012928A1/en not_active Ceased
- 2013-07-16 IN IN140MUN2015 patent/IN2015MN00140A/en unknown
- 2013-07-16 EP EP13737831.1A patent/EP2872896B1/en active Active
- 2013-07-16 CA CA2878497A patent/CA2878497C/en not_active Expired - Fee Related
- 2013-07-16 AU AU2013292040A patent/AU2013292040B2/en not_active Ceased
- 2013-07-16 CN CN201380038250.8A patent/CN104541169B/zh not_active Expired - Fee Related
- 2013-07-16 ES ES13737831.1T patent/ES2666073T3/es active Active
- 2013-07-16 PL PL13737831T patent/PL2872896T3/pl unknown
-
2015
- 2015-01-14 ZA ZA2015/00254A patent/ZA201500254B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014012928A1 (en) | 2014-01-23 |
| EP2687848A1 (en) | 2014-01-22 |
| AU2013292040B2 (en) | 2018-07-12 |
| CN104541169A (zh) | 2015-04-22 |
| NO2872896T3 (enExample) | 2018-05-26 |
| ZA201500254B (en) | 2016-06-29 |
| PL2872896T3 (pl) | 2018-08-31 |
| EA201590220A1 (ru) | 2015-06-30 |
| PT2872896T (pt) | 2018-04-02 |
| CA2878497C (en) | 2021-06-08 |
| EP2872896B1 (en) | 2017-12-27 |
| ES2666073T3 (es) | 2018-04-30 |
| EP2872896A1 (en) | 2015-05-20 |
| CA2878497A1 (en) | 2014-01-23 |
| EA030721B1 (ru) | 2018-09-28 |
| IN2015MN00140A (enExample) | 2015-10-16 |
| CN104541169B (zh) | 2017-09-15 |
| AU2013292040A1 (en) | 2015-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kampmann et al. | Interferon-γ release assays do not identify more children with active tuberculosis than the tuberculin skin test | |
| Lighter et al. | Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children | |
| Hur et al. | Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects | |
| Clifford et al. | Cytokine biomarkers for the diagnosis of tuberculosis infection and disease in adults in a low prevalence setting | |
| JP2010502200A (ja) | Ｉｐ−１０に基づく免疫学的モニタリング | |
| Goletti et al. | IFN-γ, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis | |
| DK2872896T3 (en) | Status of a tuberculosis infection in an individual | |
| Coad et al. | Simultaneous measurement of antigen-induced CXCL10 and IFN-γ enhances test sensitivity for bovine TB detection in cattle | |
| US20150153361A1 (en) | Status of Tuberculosis Infection in an Individual | |
| Eribo et al. | Host urine immunological biomarkers as potential candidates for the diagnosis of tuberculosis | |
| CN111443208A (zh) | 鉴别活动性结核病和潜伏性结核病的组合物 | |
| CN106939035B (zh) | 一种结核分枝杆菌t细胞抗原表位多肽及其应用 | |
| JP6698530B2 (ja) | インビボまたはインビトロでの細胞が介在する結核の免疫学的診断の改善のための診断試薬 | |
| Jeong et al. | Predictive factors for indeterminate result on the QuantiFERON test in an intermediate tuberculosis-burden country | |
| Villar-Hernández et al. | Development and evaluation of an NTM-IGRA to guide pediatric lymphadenitis diagnosis | |
| Shaikh et al. | Novel interferon-gamma assays for diagnosing tuberculosis in young children in India | |
| Hungria et al. | Antigen-specific secretion of IFNγ and CXCL10 in whole blood assay detects Mycobacterium leprae infection but does not discriminate asymptomatic infection from symptomatic leprosy | |
| KR20160137007A (ko) | 한국 결핵균주 항원 특이적 면역반응을 이용한 결핵진단 방법 및 키트 | |
| CN114563576B (zh) | Cxcl14作为生物标志物在结核病诊断中的用途 | |
| Silveira et al. | Contribution of the interferon-gamma release assay to tuberculosis diagnosis in children and adolescents | |
| Kempisty et al. | Interferon gamma release assays based on M. tuberculosis--specific antigens in sarcoidosis patients | |
| ZA200905156B (en) | Marker for the rapid differentiation of active TB disease from latent tuberculosis infection | |
| Jafrasteh et al. | Evaluation of interleukin-2 to detect active and latent tuberculosis among household contacts of pulmonary tuberculosis cases | |
| EP2711706A1 (en) | Mycobacterial thiolperoxidase and its use | |
| Zaida et al. | Im-mune Biomarker Combinations for Diagnosis Monitoring of Latent Tuberculosis Infection |